![Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet](https://www.thelancet.com/cms/asset/f9e3ed56-775a-4a21-9a0a-3da5102d2d2b/gr1a.jpg)
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet
![Inq, a Modern GPU-Accelerated Computational Framework for (Time-Dependent) Density Functional Theory | Journal of Chemical Theory and Computation Inq, a Modern GPU-Accelerated Computational Framework for (Time-Dependent) Density Functional Theory | Journal of Chemical Theory and Computation](https://pubs.acs.org/cms/10.1021/acs.jctc.1c00562/asset/images/medium/ct1c00562_0019.gif)
Inq, a Modern GPU-Accelerated Computational Framework for (Time-Dependent) Density Functional Theory | Journal of Chemical Theory and Computation
Alkene Synthesis by Photocatalytic Chemoenzymatically Compatible Dehydrodecarboxylation of Carboxylic Acids and Biomass | ACS Catalysis
![Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium - The Lancet Oncology Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium - The Lancet Oncology](https://www.thelancet.com/cms/attachment/38e01846-c7c7-430d-8827-879c0dd57cc0/gr1.jpg)
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium - The Lancet Oncology
![Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/d557c858-844a-4623-824b-9e1efe750d5d/gr1.jpg)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
![Oxygen | Free Full-Text | Free Radical Properties, Source and Targets, Antioxidant Consumption and Health Oxygen | Free Full-Text | Free Radical Properties, Source and Targets, Antioxidant Consumption and Health](https://pub.mdpi-res.com/oxygen/oxygen-02-00006/article_deploy/html/images/oxygen-02-00006-g001.png?1650243270)